Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Accounts Payables: 2020-2023

Historic Accounts Payables for Candel Therapeutics (CADL) over the last 3 years, with Sep 2023 value amounting to $250,000.

  • Candel Therapeutics' Accounts Payables fell 74.23% to $250,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $250,000, marking a year-over-year decrease of 74.23%. This contributed to the annual value of $380,000 for FY2022, which is 76.10% down from last year.
  • As of Q3 2023, Candel Therapeutics' Accounts Payables stood at $250,000, which was down 47.92% from $480,000 recorded in Q2 2023.
  • Candel Therapeutics' 5-year Accounts Payables high stood at $1.6 million for Q4 2021, and its period low was $250,000 during Q3 2023.
  • For the 3-year period, Candel Therapeutics' Accounts Payables averaged around $891,600, with its median value being $842,000 (2021).
  • Examining YoY changes over the last 5 years, Candel Therapeutics' Accounts Payables showed a top increase of 108.70% in 2022 and a maximum decrease of 76.10% in 2022.
  • Over the past 4 years, Candel Therapeutics' Accounts Payables (Quarterly) stood at $921,000 in 2020, then spiked by 72.64% to $1.6 million in 2021, then crashed by 76.10% to $380,000 in 2022, then plummeted by 74.23% to $250,000 in 2023.
  • Its Accounts Payables stands at $250,000 for Q3 2023, versus $480,000 for Q2 2023 and $592,000 for Q1 2023.